Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide, an amylin analog, enhances the weight loss effects of semaglutide or tirzepatide by slowing gastric emptying, suppressing glucagon, and reducing appetite. It works synergistically with Switching to Tirzepatide 5 mg From Glucagon Like Peptide 1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment Endocrine Practice cagrisema #tirzepatide #cagrilintide #semaglutide #obesity #weightloss #redefine4 Martin Haluzk